Figure 2.

Actual values, change from baseline to months 12 and 24, and change from month 12 to month 24 in A, modified Sharp/van der Heijde score (SHS), B, erosion score, and C, joint space narrowing score in rheumatoid arthritis (RA) patients receiving tofacitinib 5 mg twice daily (BID) and RA patients receiving tofacitinib 10 mg twice daily (as observed in the full analysis set). All patients received background methotrexate. Patients who did not have valid postbaseline radiographs were not included. Data are shown for patients who completed month 12, as observed. Values are the mean ± SEM (n = 287 at baseline, n = 252 at month 12, and n = 210 at month 24 [n = 208 for change from month 12] for tofacitinib 5 mg twice daily; n = 298 at baseline, n = 261 at month 12, and n = 216 at month 24 [n = 214 for change from month 12] for tofacitinib 10 mg twice daily).